We Offer Worldwide Shipping
Login Wishlist

Fangchinoline

$78

  • Brand : BIOFRON

  • Catalogue Number : BF-F2008

  • Specification : 98%

  • CAS number : 436-77-1

  • Formula : C37H40N2O6

  • Molecular Weight : 608.72

  • PUBCHEM ID : 73481

  • Volume : 20mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-F2008

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

608.72

Appearance

White crystalline powder

Botanical Source

Stephania tetrandra

Structure Type

Alkaloids

Category

Standards;Natural Pytochemical;API

SMILES

CN1CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)CC6C7=C(O3)C(=C(C=C7CCN6C)OC)O)OC)OC

Synonyms

Berbaman-7-ol, 6,6',12-trimethoxy-2,2'-dimethyl-/Fangquinoline/FF-0018/d,l-Fangchinolin/(S,S)-(+)-tetrandine/12-O-MethylatherosperMoline/(1β)-6,6',12-Trimethoxy-2,2'-dimethylberbaman-7-ol/Tetrandrine B/6,6',12-Trimethoxy-2,2'-dimethylberbaman-7-ol/Hanfangichin B/N1799/I06-1344/THALRUGOSINE/Fangchinoline/7-o-demethyltetrandrine

IUPAC Name

(1S,14S)-9,20,25-trimethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.23,6.18,12.114,18.027,31.022,33]hexatriaconta-3(36),4,6(35),8,10,12(34),18,20,22(33),24,26,31-dodecaen-21-ol

Density

1.2±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

383.0±32.9 °C

Boiling Point

709.7±60.0 °C at 760 mmHg

Melting Point

InChl

InChI=1S/C37H40N2O6/c1-38-14-12-24-19-31(42-4)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-32-18-23(8-11-30(32)41-3)17-29-35-25(13-15-39(29)2)20-34(43-5)36(40)37(35)45-33/h6-11,18-21,28-29,40H,12-17H2,1-5H3/t28-,29-/m0/s1

InChl Key

IIQSJHUEZBTSAT-VMPREFPWSA-N

WGK Germany

RID/ADR

HS Code Reference

2924290000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:436-77-1) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

Title

ESICM LIVES 2016: part threeMilan, Italy. 1-5 October 2016

Publish date

2016 Sep 29

PMID

26640625

Abstract

Background
The treatment of unstable intertrochanteric fractures in elderly is still controversial. The purpose of this study is to present treatment strategies for unstable intertrochanteric fractures with hemiarthroplasty using standard uncemented collared femoral stems and at the same time preserving the fractured calcar fragment.

Methods
Fifty-four patients aged 75 years or older with unstable intertrochanteric fractures were included in this prospective cohort study. All patients were treated with calcar preserving hemiarthroplasty using cementless collored femoral stems. Fractured calcar fragment was stabilized either by compaction between the implant and femur or fixed with cable grip system. Follow-up evaluations were performed at least 24 months and later. Palmer and Parker mobility score and visual analogue scale (VAS) pain score were assessed. We also analyzed radiographs of the operated hip at each follow-up visit.

Results
The patients were 15 males and 39 females with a mean age of 81.3 years (range, 75 to 93 years). The average operative time was 86.6 minutes. The mean transfused blood units were 1.2 units. The average duration of hospital stay was 5.3 days. The preoperative mean mobility score was 6.20. This score was found to be 4.96 on postoperative third day and 5.90 at 24 months postoperatively. The results of the statistical analysis revealed significant increase in the mobility scores at each follow-up after three days. Radiological interpretation revealed no loosening in the cable-grip systems, and no significant subsidence (> 5 mm) of prosthesis was observed.

Conclusions
Calcar preservation arthroplasty is a good option for elderly patients with severe osteoporosis, frail constitution and the patients who are at higher risk for second operation due to unstable intertrochanteric fractures.

KEYWORDS

Hemiarthroplasty, Hip fractures, Weight-bearing

Title

Calcar Preservation Arthroplasty for Unstable Intertrochanteric Femoral Fractures in Elderly

Author

Mustafa Celiktas, MD,corresponding author Emre Togrul, MD, and Ozkan Kose, MD*

Publish date

2015 Dec

PMID

28293470

Abstract

Background
Arginine vasopressin 1B receptor (V1B) antagonists may have utility for the treatment of major depressive disorder (MDD).

Methods
The V1B antagonist ABT‐436 (N = 31) or matching placebo (N = 20) was administered to MDD subjects for 7 days. The main study objectives were to assess the safety and hypothalamic-pituitary-adrenal axis (HPA) effects of ABT‐436 in MDD subjects. MDD symptoms were assessed using the 17‐item Hamilton Depression Rating Scale (HAM‐D‐17) and the subject‐rated Mood and Anxiety Symptom Questionnaire (MASQ).

Results
The most prevalent safety finding associated with ABT‐436 800 mg QD was increased mild‐moderate diarrhea (68% v 5%, p < 0.001). Increased nausea (26% v 5%, p < 0.10), decreased systolic blood pressure (3.15-3.44 mmHg, p < 0.10) and increased heart rate (3.42-4.01 bpm, p < 0.05) were also associated with ABT‐436 800 mg QD. Basal HPA activity measured by 24‐hr urine total glucocorticoids was 25% lower with ABT‐436 than placebo (p < 0.001). The reduction was, on average, larger in subjects with higher baseline urine total glucocorticoids. Results on plasma adrenocorticotrophic hormone (ACTH), urine, serum and saliva cortisol, and saliva cortisone also showed basal HPA attenuation with ABT‐436. Dynamic HPA activity measured by plasma ACTH and serum cortisol responses to corticotrophin releasing hormone (CRH) were 30-46% lower in ABT‐436 subjects (all p < 0.001). Each ABT‐436 subject showed response to CRH in or near the baseline range of responses. ABT‐436 was associated with more favorable symptom changes on two of five MASQ subscales (estimated effect size 1.47-1.86, p < 0.01) but not on HAM‐D‐17.

Conclusions
The results support further clinical study of the antidepressant potential of ABT‐436.

KEYWORDS

antidepressants, biological markers, clinical trials, depression, measurement/psychometrics, mood disorders, pharmacotherapy

Title

Hypothalamic‐pituitary‐adrenal axis and depression symptom effects of an arginine vasopressin type 1B receptor antagonist in a one‐week randomized Phase 1b trial

Author

David A. Katz,corresponding author 1 Charles Locke, 1 Nicholas Greco, 1 Wei Liu, 1 and Katherine A. Tracy 1

Publish date

2017 Mar;


Description :

Empty ...